Literature DB >> 25511096

[Analysis of traditional cardiovascular risk factors in patients with systemic lupus erythematosus].

Li Liu1, Tingting Zhang1, Yicong Ye1, Shuyang Zhang2, Lianfeng Chen1.   

Abstract

OBJECTIVE: To evaluation the prevalence of hypertension, diabetes, dyslipidemia in systemic lupus erythematosus (SLE) patients, and investigate the factors that affecting lipid levels in SLE patients.
METHODS: A total of 540 adult SLE patients hospitalized in Peking Union Medical College Hospital from March 2010 to March 2013 were retrospectively included (SLE group), and 1 080 gender and age matched (1: 2) healthy controls were selected from our medical examination center (control group). The prevalence rate of hypertension, diabetes, dyslipidemia and the levels of serum lipid were compared between the two groups, the factors affecting lipid levels in SLE patients were also analyzed.
RESULTS: The percentage of hypertension, diabetes, dyslipidemia, elevated total cholesterol (TC), elevated triglyceride (TG), decreased high density lipoprotein cholesterol (HDL-C) and elevated low density lipoprotein cholesterol (LDL-C) in SLE patients were significantly higher than those in healthy controls (all P < 0.01) . Compared with the control group, SLE patients had significantly higher TC, TG, LDL-C levels and significantly lower HDL-C levels (all P < 0.01) . Multifactor regression analysis showed that TC and LDL-C levels were positively correlated with lupus nephritis (β = 0.695,0.437), corticosteroids therapy (β = 1.195, 0.715), complement C4 levels (β = 4.817, 3.382) and 24 hours urine protein content (β = 0.112, 0.078) (all P < 0.01) , but negatively correlated with serum albumin (Alb) (β = -0.107, -0.077) and high sensitive C reactive protein (hsCRP) levels (β = -0.021, -0.014) (all P < 0.01). TG levels were positively correlated with lupus nephritis (β = 0.359) and 24 hours urine protein content (β = 0.045) (both P < 0.05), negatively correlated with male gender (β = -0.605), age (β = -0.014) and Alb levels (β = -0.053) (P < 0.01 or 0.05). HDL-C levels were positively correlated with age (β = 0.007), lupus nephritis (β = 0.188), corticosteroids therapy (β = 0.342), consecutive 30 days cumulative corticosteroids dose before serum lipid were measured (β<0.001), and complement C3 levels(β = 0.351) (all P < 0.01) , negatively correlated with hsCRP levels (β = -0.005, P < 0.01). Serum lipid levels did not correlate with disease duration, disease activity, corticosteroids therapy time, corticosteroids daily dose before serum lipid measurement, serum creatinine levels and erythrocyte sedimentation rate (ESR) (all P > 0.05).
CONCLUSION: The prevalence rate of hypertension, diabetes and dyslipidemia in SLE hospitalized patients are significantly higher compared to normal controls and lipid levels of SLE patients are related to various SLE disease factors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25511096

Source DB:  PubMed          Journal:  Zhonghua Xin Xue Guan Bing Za Zhi        ISSN: 0253-3758


  4 in total

Review 1.  Dyslipidemia in systemic lupus erythematosus.

Authors:  Melinda Zsuzsanna Szabó; Peter Szodoray; Emese Kiss
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

2.  Systemic Lupus Erythematosus and Cardiovascular Disease: A Mendelian Randomization Study.

Authors:  Ning Gao; Minjian Kong; Xuebiao Li; Dongdong Wei; Xian Zhu; Ze Hong; Ming Ni; Yifan Wang; Aiqiang Dong
Journal:  Front Immunol       Date:  2022-06-06       Impact factor: 8.786

3.  Elevated serum cholesterol levels are associated with proteinuria over 0.5 g/day in premenopausal women with systemic lupus erythematosus.

Authors:  Haijun Liu; Qianhua Li; Xiuning Wei; Jianda Ma; KangXia Long; Xia Ouyang; Nemin Liu; Yongsheng Li; Liping He; Lie Dai; Xiaoyan Cai
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

4.  Frequency of Dyslipidemia in patients with Lupus Nephritis.

Authors:  Saba Sajjad; Sumaira Farman; Muhammad Ahmed Saeed; Nighat Mir Ahmad; Bilal Azeem Butt
Journal:  Pak J Med Sci       Date:  2017 Mar-Apr       Impact factor: 1.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.